-The Hindu Public health experts agree that the response to the pandemic depends on constant surveillance and monitoring the evolution of the viral strain A viral storm is raging across the country. More than 200 deaths due to Influenza A (H1N1), known as swine flu, have been recorded within a short period of over a month. Telangana, has the dubious distinction of recording over 50 deaths and more than 600 H1N1-positive cases...

-The Hindu Tropical diseases have often been neglected by pharmaceuticals because the size of the drug market is smaller, people have lower incomes and companies are uncertain about IPR January marked an important breakthrough in the fight against tropical diseases. Researchers and the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Delhi found a drug candidate that prevented TB and malaria pathogens from infecting human blood cells. It is not just that...

-The Indian Express The World Universal Health Coverage Day, observed on December 12, builds on growing global momentum towards introducing universal health coverage (UHC) in national health plans and reinforces the case for including UHC as a prominent sustainable development goal to be adopted by the UN next year. India proposes to implement a programme of national health assurance, which embraces the principles of UHC. It is expected that the government...

-The Hindu Obamacare and other such examples make a compelling case for seeking the right combination of roles for the public and private sector in health reform in India Nail or screw? Which is best to join pieces of wood? In carpentry, the answer is that each offers benefits depending on the application. With health care reform, the choice of public or private sector financing, delivery and regulation is subject to a...

-The Times of India Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes. Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile,...